Samsung is a multinational conglomerate company headquartered in Seoul, South Korea, which is comprised of a multitude of subsidiaries and affiliated businesses in electronics, ship building, construction and more. Samsung invested the 2nd-greatest amount of money into research and development of any company worldwide in 2014; it’s $13.4 billion R&D investment that year was slightly edged by Volkswagen’s $13.5 billion…

There was a lot of action on this in the last Congress. There is a group of law professors that have expressed some opposition to the proposal to add a civil remedy, in spite of widespread support among industry stakeholders. There was some controversy around some seizure provisions that were suggested in one version of the legislation. And I think those discussions will usefully inform what will be done in this Congress. But I believe there is a great deal of support for making that basic change to allow companies to have another—not a displacement, not preemptive of state law but an additional place to go to get the benefit of nationwide service of process and other special advantages of being in federal court.

The Boston Scientific Corporation (NYSE: BSX), officially headquartered in Marlborough, MA, is a developer and manufacturer of medical device products. Its devices are used in a diverse set of medical specialities including neuromodulation, vascular surgery, oncology, radiology and interventional cardiology. Boston Scientific’s research and development goals are aided by a network of three innovation centers for developing products as well…

The speedy evolution of what defines IoT is why the phrase is frequently called a concept, although it is best to say that the IoT describes the not too distant future where ordinary, everyday objects are connected to the Internet. That means that those objects, which can range from wearable devices to washing machines to lamps and coffee makers, will not only be able to relate to the user, but will be able to relate to one another and act in unison. It is against this backdrop that ICAP Patent Brokerage is going to be holding an Internet of Things auction on April 23, 2015. This auction will sell patent portfolios relating to wearables, smart-home technology, medical records and medical data collection, shipping and retail logistics/data, Big Data (including distributed storage architecture), sensors (MEMS and motion sensors), and the standards that drive the connectivity between them (802.11, NFC, Bluetooth, RFID, Zigbee, and PLC).

While there has been much written in the past months on efforts to change the U.S. patent system, there has been little focus on the vital role that the current patent system plays in supporting universities in conducting basic research and development (R&D). This university-driven R&D is a critical force in driving innovation, inventions and often startups that create jobs and promote American competitiveness.

Merry Lynn Morris, a faculty member USF, affected by a tragedy that left her father wheel chair bound for 21 years, created an Omni-Directional, Hands-Free Rolling Dance Chair to give those in wheel chairs new freedom and independence that most wheel chairs do not allow.

There is nothing wrong with dreaming, but there is an extremely important cautionary tale to be told about the tremendous harm that can be done to opportunity when inventors exaggerate the market size for their invention. People with money or those who control distribution channels don’t usually prefer to do business with those who are not professional. They also don’t appreciate exaggeration because it screams that you are unrealistic, which means you will be difficult to work with in the long run. Nobody enters a business deal with someone when they think they will only create a headache.

The USPTO will soon publish the Final Rules governing processing and examination of international design applications filed pursuant to the Hague Agreement. The Agreement and the USPTO’s Final Rules are all expected to go into effect on May 13, 2015. U.S. design patents resulting from applications filed on or after May 13, 2015 will have a 15 year term.

Apparently, despite the fact that there are strict page limits imposed at the Federal Circuit, Soverain was somehow supposed to fully brief all of the issues directly raised by Newegg, as well as all of the issues an activist Federal Circuit could possibly imagine. To call this a ridiculous burden doesn’t begin to scratch the surface. The Federal Circuit is depriving Soverain of property rights without due process, period. The lack of process afforded Soverain both in the Newegg case and in the Victoria Secret case should shock everyone.

Chevron pioneers many innovations in energy systems and related fields and in recent years has focused on ocean bottom sensing tech for deepwater fields, waterflood surveillance data tools for oilfields as well as heavy-duty engine oils. The company also supports technology developments pursued by open innovation initiatives like the Cleantech Open, a clean technology innovation and small-business development organization of which Chevron is a global member. In 2013, the corporation posted expenditures of $685 million on other exploration expenses, which includes R&D spending.

During our interview Lee explains that she is supportive of expanding trade agreements currently under consideration in Congress, that she looks forward to working on patent quality and receiving feedback from stakeholders on how the Office can better address patent quality, and she explained that the Office was pleased with the recent Federal Circuit ruling in In re Cuozzo Speed Technologies, which is the first appeal of a final decision of the Patent Trial and Appeal Board (PTAB) in an Inter Partes Review (IPR) proceeding.

It would be extremely unsettling if the Supreme Court has weakened Judge Lourie’s resolve to independently and properly interpret the Patent Act. If there is another explanation for his flip-flop on matters of patent eligibility I would love to hear it, but so far an explanation for diametrically different opinions has not been forthcoming. I don’t expect Judge Lourie to make a speech or hold a press conference like a politician, but if he is going to make diametrically opposite decisions in the same case, on the same facts, relating to the same claims, he owes litigants and the industry an explanation. Without an explanation it makes the entire process seem nothing more than arbitrary and capricious.

With the Euro once again in crisis people look back on the decision to go with the common currency and many people here believe that that was a step too far. That engaging in the expectation that if we do this it will naturally bring us closer together was perhaps way too optimistic. And too risky. And that risking the kind of fiscal instability that we have seen recently in order to push everyone towards a closer political union some people are saying now was a very bad bet to make, without a real supra-national bank and without having first knitted the countries together better politically.

Congressman Darrell Issa (R-CA), a member of the House Judiciary Committee and the Chair of the Subcommittee on Courts, Intellectual Property, and the Internet, struck a defiant tone this morning speaking at the National Press Club. Issa explained in no uncertain terms that the patent litigation reforms contained within the Innovation Act will not be watered down, period. He told the audience that never again will a defendant first learn of the allegations against them only at the end of the case.

The University of California maintains a portfolio of 11,556 active patent grants. Patented technologies which are currently available for licensing through UC include laser scanners for eye tracking, cardiovascular disorder treatments and environmentally friendly water treatment techniques. In 2013, the Regents of the University of California were issued 399 patents by the U.S. Patent and Trademark Office, tied for 89th-most. A great percentage of UC’s 2014 inventions were related to providing methods involving nucleic acids, host cells and pharmaceutical compositions.